Loading
Life sciences · Journal article
Frontiers in Cell and Developmental Biology · September 9, 2026
Raises a question worth testing. It does not answer one.
DNV-TC is a proposed four-dimensional computational classification system that integrates developmental biology with network medicine to stratify tumors by reactivated developmental programs and network vulnerability. The framework was applied retrospectively to published data and yielded associations between network vulnerability class and therapy response, but these analyses are in silico and retrospective; the authors explicitly state that prospective external validation is required before clinical application.
Retrospective computational analysis; classification framework proposal. Representative tumor types; specific eligibility criteria, setting, and patient cohort details not provided in abstract.. Intervention: DNV-TC classification system stratifying tumors by reactivated developmental program, network architectural vulnerability, cascade expansion phenotype, and metastatic propensity.. Compared with: TNM staging for metastasis-free survival prediction; standard classification systems for prognostic value..
Tumors with high network vulnerability showed 87% response rate to targeted therapies but developed resistance with median 6–8 months. Network vulnerability class retained independent prognostic value after adjustment for stage, grade and age (HR 2.3, 95% CI 1.8–2.9, p < 0.001). Metastatic propensity class outperformed TNM staging for 5-year metastasis-free survival prediction (AUC 0.842 versus 0.712, p < 0.001).
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The framework is presented as mechanistically grounded and potentially useful for rational therapeutic target selection, but clinicians should not apply DNV-TC to guide treatment decisions until prospective external validation is complete. The high response rates and prognostic associations are suggestive but remain in silico projections without prospective clinical confirmation.
A retrospective, in silico classification framework proposal with no prospective validation, experimental confirmation, or clinical trial evidence; the authors explicitly acknowledge the need for external validation.
As stated by the source record.
Quoted from the source exactly as published.
The framework is presented as mechanistically grounded and potentially useful for rational therapeutic target selection, but clinicians should not apply DNV-TC to guide treatment decisions until prospective external validation is complete. The high response rates and prognostic associations are suggestive but remain in silico projections without prospective clinical confirmation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Introduction Current tumor classification systems based on histology and molecular subtypes inadequately capture the functional complexity of cancer biology. Tumors frequently reactivate embryonic developmental programs, becoming dependent on master regulators that govern pluripotency, differentiation and tissue morphogenesis. This developmental reactivation creates architectural vulnerabilities in gene regulatory networks that can be therapeutically exploited. Methods We propose DNV-TC, a four-dimensional classification system that stratifies tumors according to the reactivated developmental program, network architectural vulnerability, cascade expansion phenotype and metastatic propensity. The system integrates developmental biology with network medicine through three quantitative indices computed on multi-layer gene regulatory networks: the tumor developmental regulatory impact (T-DRI), tumor disease network vulnerability (TD-NV) and cascade expansion index-tumor (CEI-T). DNV-TC was applied retrospectively to representative tumor types using published molecular and clinical data. Results Tumors with high network vulnerability showed marked responses to targeted therapies (87% response rate) but rapidly developed resistance (median 6–8 months), while tumors with reactivated pluripotency programs displayed cancer stem-cell characteristics and therapeutic resistance. Network vulnerability class retained independent prognostic value after adjustment for stage, grade and age (HR 2.3, 95% CI 1.8–2.9, p < 0.001), and metastatic propensity class outperformed TNM staging for 5-year metastasis-free survival prediction (AUC 0.842 versus 0.712, p < 0.001). Discussion DNV-TC provides a mechanistically grounded classification system that bridges developmental biology and precision oncology, thus enabling rational selection of therapeutic targets and combination strategies. The present analyses are retrospective and in silico, and prospective external validation is required.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.